SciClone Pharmaceuticals Inc. said growth in sales of its skin cancer drug to China will fuel revenue growth of 7 percent to 10 percent this year.

The biopharmaceuticals company projects full-year sales of $35 million to $36 million, due largely to sales of Zadaxin, its treatment for malignant melanoma. The drug is approved for market in China but is still undergoing mid-stage clinical trials in the U.S.

SciClone estimates a full-year loss of $7 million, or 15 cents per share. Last year, SciClone posted earnings of $727,000, or 2 cents per share -- the bulk of which came from an $8 million settlement gain on a clinical trial dispute. In 2005, the company lost $7.7 million, or 17 cents per share. Revenue for the full year totaled $32.7 million, up from $28.3 million.

Source:佚名